The interruption of transmission of onchocerciasis in Kaduna, Kebbi and Zamfara states, Nigeria: another milestone achievement.
Simulium
Ov16 serological assessment
black flies
entomological assessment
onchocerciasis
stopping mass drug administration
Journal
International health
ISSN: 1876-3405
Titre abrégé: Int Health
Pays: England
ID NLM: 101517095
Informations de publication
Date de publication:
21 09 2022
21 09 2022
Historique:
received:
15
12
2021
revised:
02
02
2022
accepted:
12
05
2022
entrez:
21
9
2022
pubmed:
22
9
2022
medline:
24
9
2022
Statut:
ppublish
Résumé
More than 40 million people live in onchocerciasis-endemic areas in Nigeria. For at least 19 y, mass drug administration (MDA) with ivermectin was implemented with at least 65% total population coverage in Kaduna, Kebbi and Zamfara states. Impact surveys done using skin biopsies yielded no infections. Serological and entomological assessments were undertaken to determine if onchocerciasis transmission had been interrupted and MDA could be stopped. The presence of onchocerciasis-specific immunoglobulin G4 antibody was measured by enzyme=linked immunosorbent assay conducted on dried blood spots collected from 5- to 9-year-old children resident in each state. O-150 polymerase chain reaction testing of Simulium damnosum s.l. heads for Onchocerca volvulus DNA was done on black flies collected by human landing capture and Esperanza window traps. A total of 9078 children were surveyed across the three states. A total of 6139 vectors were collected from Kaduna state, 129 from Kebbi state and 2 from Zamfara state; all were negative. Kebbi and Zamfara states did thousands of hours of black fly catching and intensive river prospecting. The resulting low fly catch was due to a low fly population incapable of sustaining transmission. Onchocerciasis transmission has been interrupted and the three states meet World Health Organization thresholds: seropositivity in children <0.1% and <1/2000 infective black flies with 95% confidence. The 2.2 million people in Kaduna state and 4 million in Kebbi and Zamfara states no longer need ivermectin for onchocerciasis.
Sections du résumé
BACKGROUND
More than 40 million people live in onchocerciasis-endemic areas in Nigeria. For at least 19 y, mass drug administration (MDA) with ivermectin was implemented with at least 65% total population coverage in Kaduna, Kebbi and Zamfara states. Impact surveys done using skin biopsies yielded no infections. Serological and entomological assessments were undertaken to determine if onchocerciasis transmission had been interrupted and MDA could be stopped.
METHODS
The presence of onchocerciasis-specific immunoglobulin G4 antibody was measured by enzyme=linked immunosorbent assay conducted on dried blood spots collected from 5- to 9-year-old children resident in each state. O-150 polymerase chain reaction testing of Simulium damnosum s.l. heads for Onchocerca volvulus DNA was done on black flies collected by human landing capture and Esperanza window traps.
RESULTS
A total of 9078 children were surveyed across the three states. A total of 6139 vectors were collected from Kaduna state, 129 from Kebbi state and 2 from Zamfara state; all were negative. Kebbi and Zamfara states did thousands of hours of black fly catching and intensive river prospecting. The resulting low fly catch was due to a low fly population incapable of sustaining transmission.
CONCLUSION
Onchocerciasis transmission has been interrupted and the three states meet World Health Organization thresholds: seropositivity in children <0.1% and <1/2000 infective black flies with 95% confidence. The 2.2 million people in Kaduna state and 4 million in Kebbi and Zamfara states no longer need ivermectin for onchocerciasis.
Identifiants
pubmed: 36130252
pii: 6694762
doi: 10.1093/inthealth/ihac036
pmc: PMC9492257
doi:
Substances chimiques
Immunoglobulins
0
Immunosorbents
0
Ivermectin
70288-86-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
ii43-ii54Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.
Références
World Health Organ Tech Rep Ser. 1995;852:1-104
pubmed: 7541171
Am J Trop Med Hyg. 2016 Aug 3;95(2):417-425
pubmed: 27215297
Parasitol Today. 1991 May;7(5):97-9
pubmed: 15463457
PLoS Negl Trop Dis. 2012;6(6):e1712
pubmed: 22724041
Am J Trop Med Hyg. 2017 Oct;97(4):1235-1242
pubmed: 29031285
Bull World Health Organ. 1997;75(3):229-36
pubmed: 9277010
Am J Trop Med Hyg. 1999 Jan;60(1):124-8
pubmed: 9988335
Am J Trop Med Hyg. 2018 Sep;99(3):749-752
pubmed: 30014821
Am J Trop Med Hyg. 2020 Mar;102(3):582-592
pubmed: 32043442
Res Rep Trop Med. 2012 May 18;3:21-33
pubmed: 30890864
Am J Trop Med Hyg. 2004 Jan;70(1):38-45
pubmed: 14971696
Ann Trop Med Parasitol. 1994 Oct;88(5):463-74
pubmed: 7979636
Res Rep Trop Med. 2020 Oct 07;11:81-95
pubmed: 33117052
PLoS Negl Trop Dis. 2018 May 3;12(5):e0006471
pubmed: 29723238
Trop Med Int Health. 1998 Dec;3(12):951-61
pubmed: 9892280
Wkly Epidemiol Rec. ;91(43):501-5
pubmed: 27801556
Int Health. 2018 Mar 1;10(suppl_1):i27-i32
pubmed: 29471346
Int Health. 2018 Mar 1;10(suppl_1):i71-i78
pubmed: 29471334
Wkly Epidemiol Rec. 2008 Aug 22;83(34):307-12
pubmed: 18720576
PLoS Negl Trop Dis. 2009 Jul 21;3(7):e497
pubmed: 19621091
Tropenmed Parasitol. 1981 Mar;32(1):2-16
pubmed: 7015637
Ann Trop Med Parasitol. 1995 Feb;89(1):31-8
pubmed: 7741592
Parasit Vectors. 2012 Feb 07;5:28
pubmed: 22313631